When will margetuximab be included in medical insurance?

Margetuximab (margetuximab), as a monoclonal antibody targeting the HER2 receptor, has been officially launched in China in recent years, providing a new treatment option for patients with HER2-positive breast cancer. Although the original version of the drug has entered the domestic market, due to its short time on the market, the price is not yet completely clear, and it is not included in the national medical insurance directory. Therefore, when purchasing and using this drug, patients still need to consult regular medical institutions or pharmacies for the latest price and payment policies.

Regarding the possibility of margetuximab being included in medical insurance in the future, it usually needs to go through a series of approval procedures, including clinical efficacy evaluation, drug safety review and economic evaluation. In view of the clinical performance and efficacy of the drug being recognized internationally and the increasing demand for targeted drugs from domestic patients, the industry generally believes that the inclusion of margetuximab in medical insurance is expected to be gradually advanced in the next one to two years. The specific time will depend on the approval pace and negotiation results of the National Medical Insurance Bureau.

In terms of price, margituximab has European and Japanese versions of the original drug available in overseas markets. The common specifications are250mg/10ml one bottle per box, and the price is about more than 30,000 yuan. The price will fluctuate due to exchange rates and market factors. At present, there is no generic version of the drug in China, which means that if patients need to take the drug, they mainly rely on the supply of the original drug, and the price pressure is relatively high.

In general, although margetuximab is already on the market in China, it is not included in medical insurance. Patients need to pay attention to relevant policy developments and use the drug rationally under the guidance of doctors. With the promotion of its clinical application and the deepening of medical insurance negotiations, it is expected that medical insurance coverage will be achieved in the next few years, thereby reducing the financial burden on patients and improving drug accessibility for more patients.

Reference materials:https://www.margenza.com/